Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement

Melbourne (Australia) and Liege (Belgium) – 9 February 2022. Telix announces a global clinical supply agreement with Eckert & Ziegler for lutetium-177

Telix announces a global clinical supply agreement with Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (EZAG) for highly pure no-carrier-added (n.c.a.) lutetium-177 (177Lu), a therapeutic isotope used in Telix’s portfolio of molecularly targeted radiation (MTR) investigational products.

This agreement further enhances Telix’s existing 177Lu supplier network, which includes a commercial supply agreement with ITM Isotope Technologies Munich SE (ITM), and clinical supply agreements with the Australian Nuclear Science and Technology Organisation (ANSTO), and Eczacıbaşı-Monrol (Monrol).

As Telix advances its late-stage clinical trials using the medical radioisotope 177Lu, it is building a global supplier network with proximity to major international markets, capable of consistently delivering high-quality, no-carrier-added 177Lu to patients. Each of the partners in Telix’s carefully selected 177Lu network delivers unique operating and geographic characteristics, enabling truly global delivery of product for clinical studies and eventually commercial use.

EZAG will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer).

Dr. Gabriel Liberatore, Telix Group Chief Operating Officer stated, “We are pleased to have established this agreement with EZAG, a premier supplier of high-quality medical radioisotopes, who is now part of our global network of lutetium suppliers. We are committed to working with global partners with a reputation for delivering the highest quality isotopes, and a demonstrated commitment to environmentally sustainable production technologies. Telix’s relationship with EZAG is a multi-isotope partnership and we are delighted to include 177Lu access as part of the supply chain.”

Dr. Harald Hasselmann, Executive Director responsible for the Medical segment of Eckert & Ziegler continued, “The agreement underlines our outstanding expertise in delivering isotopes to the pharmaceutical industry. With our production facilities in Europe, Asia and in North America, we are excellently positioned to meet the increasing demand for this isotope and related development and manufacturing services. Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply 177Lu n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.”

To read the full media release please click here.

To return to Telix’s home page please click here.